A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

BACKGROUND: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for...

Full description

Saved in:
Bibliographic Details
Main Authors: M.L. Rekart, P. Thit, M. Oluya, S. Moe, T. Hasan, N. Parpieva, K. Safaev, A. Khristusev, T. Zinaida, J. Singh, S. Allamuratova, I. Azamat, C.G. Restrepo, N. Sitali, J. Achar, J.L. Alvaraez, A. Sinha
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-07-01
Series:IJTLD Open
Subjects:
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00002
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591416055824384
author M.L. Rekart
P. Thit
M. Oluya
S. Moe
T. Hasan
N. Parpieva
K. Safaev
A. Khristusev
T. Zinaida
J. Singh
S. Allamuratova
I. Azamat
C.G. Restrepo
N. Sitali
J. Achar
J.L. Alvaraez
A. Sinha
author_facet M.L. Rekart
P. Thit
M. Oluya
S. Moe
T. Hasan
N. Parpieva
K. Safaev
A. Khristusev
T. Zinaida
J. Singh
S. Allamuratova
I. Azamat
C.G. Restrepo
N. Sitali
J. Achar
J.L. Alvaraez
A. Sinha
author_sort M.L. Rekart
collection DOAJ
description BACKGROUND: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HRRS-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population). METHODS: We conducted a retrospective, descriptive study of microbiologically confirmed HRRS-TB using routinely collected programmatic data from 2009 to 2020. RESULTS: We included 854 HRRS-TB cases. Treatment success was 80.2% overall. For REZLfx, the treatment success rate was 92.0% over a short treatment duration, with no amplifications to RIF or second-line anti-TB drug resistance. We documented 46 regimens with REZLfx plus linezolid (success 87.0%) and 539 regimens using kanamycin or capreomycin (success 76.6%). We identified 37 treatment failures (4.3%), 30 deaths (3.5%), 25 resistance amplifications (2.9%), including eight to RIF (0.9%), and 99 lost to follow-up (LTFU) cases (11.6%). Unsuccessful outcomes were more common with older age, diabetes, chest X-ray cavities, smear positivity, smear-positive persistence, and male sex. LTFU was more common with injection-containing regimens. CONCLUSIONS: REZLfx is a safe and effective first-line treatment for INH-resistant, RIF-susceptible TB. Treatment success was lower and LTFU was higher for injection-containing regimens.
format Article
id doaj-art-f8ccff5dab3c476c8c68f86d9954afb5
institution Kabale University
issn 3005-7590
language English
publishDate 2024-07-01
publisher International Union Against Tuberculosis and Lung Disease (The Union)
record_format Article
series IJTLD Open
spelling doaj-art-f8ccff5dab3c476c8c68f86d9954afb52025-01-22T12:12:38ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-07-011728529110.5588/ijtldopen.23.05332A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020M.L. Rekart0P. Thit1M. Oluya2S. Moe3T. Hasan4N. Parpieva5K. Safaev6A. Khristusev7T. Zinaida8J. Singh9S. Allamuratova10I. Azamat11C.G. Restrepo12N. Sitali13J. Achar14J.L. Alvaraez15A. Sinha16Médecins Sans Frontières (MSF), Amsterdam, The Netherlands;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology, Tashkent, Uzbekistan;Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;Republican Center of Tuberculosis and Pulmonology, Nukus, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Tashkent, Uzbekistan;MSF, Berlin, Germany;Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden;MSF, London, UKMSF, London, UKBACKGROUND: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HRRS-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population). METHODS: We conducted a retrospective, descriptive study of microbiologically confirmed HRRS-TB using routinely collected programmatic data from 2009 to 2020. RESULTS: We included 854 HRRS-TB cases. Treatment success was 80.2% overall. For REZLfx, the treatment success rate was 92.0% over a short treatment duration, with no amplifications to RIF or second-line anti-TB drug resistance. We documented 46 regimens with REZLfx plus linezolid (success 87.0%) and 539 regimens using kanamycin or capreomycin (success 76.6%). We identified 37 treatment failures (4.3%), 30 deaths (3.5%), 25 resistance amplifications (2.9%), including eight to RIF (0.9%), and 99 lost to follow-up (LTFU) cases (11.6%). Unsuccessful outcomes were more common with older age, diabetes, chest X-ray cavities, smear positivity, smear-positive persistence, and male sex. LTFU was more common with injection-containing regimens. CONCLUSIONS: REZLfx is a safe and effective first-line treatment for INH-resistant, RIF-susceptible TB. Treatment success was lower and LTFU was higher for injection-containing regimens.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00002inh resistancecentral asia6rezlfxdrug-resistant tbdr-tb
spellingShingle M.L. Rekart
P. Thit
M. Oluya
S. Moe
T. Hasan
N. Parpieva
K. Safaev
A. Khristusev
T. Zinaida
J. Singh
S. Allamuratova
I. Azamat
C.G. Restrepo
N. Sitali
J. Achar
J.L. Alvaraez
A. Sinha
A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
IJTLD Open
inh resistance
central asia
6rezlfx
drug-resistant tb
dr-tb
title A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
title_full A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
title_fullStr A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
title_full_unstemmed A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
title_short A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
title_sort 10 year review of isoniazid resistant tb management in uzbekistan 2009 2020
topic inh resistance
central asia
6rezlfx
drug-resistant tb
dr-tb
url https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00002
work_keys_str_mv AT mlrekart a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT pthit a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT moluya a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT smoe a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT thasan a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT nparpieva a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT ksafaev a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT akhristusev a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT tzinaida a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jsingh a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT sallamuratova a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT iazamat a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT cgrestrepo a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT nsitali a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jachar a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jlalvaraez a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT asinha a10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT mlrekart 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT pthit 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT moluya 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT smoe 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT thasan 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT nparpieva 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT ksafaev 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT akhristusev 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT tzinaida 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jsingh 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT sallamuratova 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT iazamat 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT cgrestrepo 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT nsitali 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jachar 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT jlalvaraez 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020
AT asinha 10yearreviewofisoniazidresistanttbmanagementinuzbekistan20092020